TAMPA, Fla.--(BUSINESS WIRE)--The results of the 2024 National Diabetes Care Survey, a longitudinal analysis of patients with Type 2 diabetes in the United States, have been tabulated and offer vital insights into how cellular remote patient monitoring (RPM) can make a difference in diabetes management. The survey results show that patients, more than ever, would test their glucose more regularly if their reading was sent to their provider, and that number increased 34.8% year-over-year.

In the 2024 Diabetes Care Survey, 88.3% of participants said they would test more consistently knowing their results were being sent to their provider. With most people with Type 2 diabetes only seeing their doctor two times a year or less, they are asked to keep track of their testing numbers for long periods of time. If the patient is solely responsible for writing down their readings for review by their physician during an office visit, there may be an issue with the accuracy of those readings. It is estimated that 50% of patients don't adequately track readings or provide false readings to their doctor.1

For the third year in a row, the number of people who said they would test more consistently increased. For the same question in the 2023 National Diabetes Care Survey, 61.5% of those surveyed responded they would test more regularly. In the 2022 survey, 46.8% agreed with the same statement and only 35% agreed with that statement in 2021.

November is American Diabetes Month, a time to raise awareness for a disease that has already affected more than 38 million people in the United States. It is estimated that another approximately 98 million Americans have prediabetes. In the last 20 years, the number of Americans with diagnosed diabetes has more than doubled. According to one study, about 45% of people with diabetes don't adequately control their glucose levels.2 Testing their glucose and knowing their reading on a regular basis can help people with Type 2 diabetes better manage their disease. It is also imperative for their physician to know their daily glucose reading to provide guidance and possible adjustments to their care plan.

"When patients use a cellular-enabled glucose meter, they know their results are being sent immediately to their provider," said Dr. Bill Lewis, a member of the ClearHealth Quality Institute (CHQI) for Telemedicine Standards and Medical Advisory Board and Chair of the Telemedicine Accreditation Committee. "Smart Meter's iGlucose transmits instantly through an exclusive AT&T private data network so data is secure, accurate, and reliable every time."

Patients and providers are looking for an easy-to-use glucometer so glucose readings can be taken at home and transmitted to a healthcare professional. With cellular RPM glucose meter solutions from Smart Meter, providers are assured of getting the latest and most accurate data when a patient tests. This can help identify trends, prevent hospitalization, and improve outcomes between office visits.

Cellular-enabled monitors are some of the easiest for patients to use to test their glucose levels regularly at home. The ease-of-use and convenience of cellular-based glucose monitors leads to a better patient experience, better patient engagement and better patient adherence to care plan instructions, leading to stabilized or better control of diabetes.

You can view the complete results of the 2024 National Diabetes Care Survey here.

About Smart Meter, LLC

Smart Meter is the trusted supplier of Remote Patient Monitoring ("RPM") solutions. We empower a nationwide network of SmartPartnersTM who are working directly with healthcare providers to transform patient care. Millions of vital health data readings are reliably delivered across our platform to enable real-time, better-informed health care. Our proprietary patient-friendly cellular FDA-registered monitoring devices are connected to an exclusive AT&T 4/5G network to ensure an engaging patient experience for improved adherence. For more information, visit SmartMeterRPM.com

1 Doctors Want To See Your Glucose Meter | Prevention
2 Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors - PMC (nih.gov)

Media Contact
Keith Tolbert
keith.tolbert@iglucose.com
336-509-8024